Multiplex detection of protein-protein interactions using a next generation luciferase reporter

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1863, Issue 2, 2016, Pages 284-292

  Verhoef, Lisette G G C ^a   Mattioli, Michela ^a   Ricci, Fernanda ^a   Li, Yao Cheng ^b   Wade, Mark ^a  

^a ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Cancer; Interaction; Luciferase; MDM2; p53; PPI

Indexed keywords

FIREFLY LUCIFERASE; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; ARTHROPOD PROTEIN; INSECT PROTEIN; LUCIFERASE; MDM4 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN BINDING;

ARTICLE; CONTROLLED STUDY; DEEP SEA SPECIES; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MUTAGENESIS; PARTICLE SIZE; PHOTINUS PYRALIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SHRIMP; SIGNAL NOISE RATIO; TECHNOLOGY; VALIDATION STUDY; AMINO ACID SEQUENCE; ANIMAL; DECAPODA (CRUSTACEA); ENZYMOLOGY; FIREFLY; FLUORESCENCE MICROSCOPY; GENETICS; METABOLISM; MOLECULAR GENETICS; PROCEDURES; PROTEIN ANALYSIS; REPORTER GENE; TUMOR CELL LINE; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ARTHROPOD PROTEINS; BLOTTING, WESTERN; CELL LINE, TUMOR; DECAPODA (CRUSTACEA); FIREFLIES; GENES, REPORTER; HUMANS; INSECT PROTEINS; LUCIFERASES; MICROSCOPY, FLUORESCENCE; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84949309355     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2015.11.031     Document Type: Article

References (33)

1. Stumpf M.P., Thorne T., de Silva E., Stewart R., An H.J., Lappe M., Wiuf C. Estimating the size of the human interactome. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:6959-6964.
2. Venkatesan K., Rual J.F., Vazquez A., Stelzl U., Lemmens I., Hirozane-Kishikawa T., Hao T., Zenkner M., Xin X., Goh K.I., Yildirim M.A., Simonis N., Heinzmann K., Gebreab F., Sahalie J.M., Cevik S., Simon C., de Smet A.S., Dann E., Smolyar A., Vinayagam A., Yu H., Szeto D., Borick H., Dricot A., Klitgord N., Murray R.R., Lin C., Lalowski M., Timm J., Rau K., Boone C., Braun P., Cusick M.E., Roth F.P., Hill D.E., Tavernier J., Wanker E.E., Barabasi A.L., Vidal M. An empirical framework for binary interactome mapping. Nat Methods 2009, 6:83-90.
3. Sahni N., Yi S., Taipale M., Fuxman Bass J.I., Coulombe-Huntington J., Yang F., Peng J., Weile J., Karras G.I., Wang Y., Kovacs I.A., Kamburov A., Krykbaeva I., Lam M.H., Tucker G., Khurana V., Sharma A., Liu Y.Y., Yachie N., Zhong Q., Shen Y., Palagi A., San-Miguel A., Fan C., Balcha D., Dricot A., Jordan D.M., Walsh J.M., Shah A.A., Yang X., Stoyanova A.K., Leighton A., Calderwood M.A., Jacob Y., Cusick M.E., Salehi-Ashtiani K., Whitesell L.J., Sunyaev S., Berger B., Barabasi A.L., Charloteaux B., Hill D.E., Hao T., Roth F.P., Xia Y., Walhout A.J., Lindquist S., Vidal M. Widespread Macromolecular Interaction Perturbations in Human Genetic Disorders. Cell 2015, 161:647-660.
4. Fontaine S.N., Rauch J.N., Nordhues B.A., Assimon V.A., Stothert A.R., Jinwal U.K., Sabbagh J.J., Chang L., Stevens S.M., Zuiderweg E.R., Gestwicki J.E., Dickey C.A. Isoform selective genetic inhibition of constitutive cytosolic Hsp70 activity promotes client tau degradation using an altered co-chaperone complement. J. Biol. Chem. 2015, 290:13115-13127.
5. Arkin M.R., Tang Y., Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem. Biol. 2014, 21:1102-1114.
6. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., Liu E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
7. Patton J.T., Mayo L.D., Singhi A.D., Gudkov A.V., Stark G.R., Jackson M.W. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res. 2006, 66:3169-3176.
8. Wade M., Wong E.T., Tang M., Stommel J.M., Wahl G.M. Hdmx modulates the outcome of p53 activation in human tumor cells. J. Biol. Chem. 2006, 281:33036-33044.
9. Zaytsev A., Dodd B., Magnani M., Ghiron C., Golding B.T., Griffin R.J., Liu J., Lu X., Micco I., Newell D.R., Padova A., Robertson G., Lunec J., Hardcastle I.R. Searching for dual inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interaction by a scaffold-hopping approach. Chem. Biol. Drug Des. 2014, 86:180-189.
10. Zhao Y., Aguilar A., Bernard D., Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 inhibitors) in clinical trials for cancer treatment. J. Med. Chem. 2015, 58:1038-1052.
11. Stynen B., Tournu H., Tavernier J., Van Dijck P. Diversity in genetic in vivo methods for protein-protein interaction studies: from the yeast two-hybrid system to the mammalian split-luciferase system. Microbiol. Mol. Biol. Rev. 2012, 76:331-382.
12. DiLella A.G., Hope D.A., Chen H., Trumbauer M., Schwartz R.J., Smith R.G. Utility of firefly luciferase as a reporter gene for promoter activity in transgenic mice. Nucleic Acids Res. 1988, 16:4159.
13. Conti E., Franks N.P., Brick P. Crystal structure of firefly luciferase throws light on a superfamily of adenylate-forming enzymes. Structure 1996, 4:287-298.
14. Ozawa T., Umezawa Y. Detection of protein-protein interactions in vivo based on protein splicing. Curr. Opin. Chem. Biol. 2001, 5:578-583.
15. Luker K.E., Smith M.C., Luker G.D., Gammon S.T., Piwnica-Worms H., Piwnica-Worms D. Kinetics of regulated protein-protein interactions revealed with firefly luciferase complementation imaging in cells and living animals. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:12288-12293.
16. Branchini B.R., Southworth T.L., Murtiashaw M.H., Wilkinson S.R., Khattak N.F., Rosenberg J.C., Zimmer M. Mutagenesis evidence that the partial reactions of firefly bioluminescence are catalyzed by different conformations of the luciferase C-terminal domain. Biochemistry 2005, 44:1385-1393.
17. Nakatsu T., Ichiyama S., Hiratake J., Saldanha A., Kobashi N., Sakata K., Kato H. Structural basis for the spectral difference in luciferase bioluminescence. Nature 2006, 440:372-376.
18. Hida N., Awais M., Takeuchi M., Ueno N., Tashiro M., Takagi C., Singh T., Hayashi M., Ohmiya Y., Ozawa T. High-sensitivity real-time imaging of dual protein-protein interactions in living subjects using multicolor luciferases. PLoS One 2009, 4.
19. Villalobos V., Naik S., Bruinsma M., Dothager R.S., Pan M.H., Samrakandi M., Moss B., Elhammali A., Piwnica-Worms D. Dual-color click beetle luciferase heteroprotein fragment complementation assays. Chem. Biol. 2010, 17:1018-1029.
20. Hall M.P., Unch J., Binkowski B.F., Valley M.P., Butler B.L., Wood M.G., Otto P., Zimmerman K., Vidugiris G., Machleidt T., Robers M.B., Benink H.A., Eggers C.T., Slater M.R., Meisenheimer P.L., Klaubert D.H., Fan F., Encell L.P., Wood K.V. Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. ACS Chem. Biol. 2012, 7:1848-1857.
21. Li Y.C., Rodewald L.W., Hoppmann C., Wong E.T., Lebreton S., Safar P., Patek M., Wang L., Wertman K.F., Wahl G.M. A versatile platform to analyze low-affinity and transient protein-protein interactions in living cells in real time. Cell Rep. 2014, 9:1946-1958.
22. Yu Y., Lutz S. Circular permutation: a different way to engineer enzyme structure and function. Trends Biotechnol. 2011, 29:18-25.
23. Zhao J., Nelson T.J., Vu Q., Truong T., Stains C.I. Self-assembling nanoluc luciferase fragments as probes for protein aggregation in living cells. ACS Chem. Biol. 2015, 10.1021/acschembio.5b00758.
24. Poyurovsky M.V., Katz C., Laptenko O., Beckerman R., Lokshin M., Ahn J., Byeon I.J., Gabizon R., Mattia M., Zupnick A., Brown L.M., Friedler A., Prives C. The C terminus of p53 binds the N-terminal domain of MDM2. Nat. Struct. Mol. Biol. 2010, 17:982-989.
25. Santucci M., Vignudelli T., Ferrari S., Mor M., Scalvini L., Bolognesi M.L., Uliassi E., Costi M.P. The hippo pathway and YAP/TAZ-TEAD protein-protein interaction as targets for regenerative medicine and cancer treatment. J. Med. Chem. 2015, 58:4857-4873.
26. Muller I., Larsson K., Frenzel A., Oliynyk G., Zirath H., Prochownik E.V., Westwood N.J., Henriksson M.A. Targeting of the MYCN protein with small molecule c-MYC inhibitors. PLoS One 2014, 9.
27. Wilson R.C., Tambe A., Kidwell M.A., Noland C.L., Schneider C.P., Doudna J.A. Dicer-TRBP complex formation ensures accurate mammalian microRNA biogenesis. Mol. Cell 2015, 57:397-407.
28. Popowicz G.M., Czarna A., Wolf S., Wang K., Wang W., Domling A., Holak T.A. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle 2010, 9:1104-1111.
29. Stacer A.C., Nyati S., Moudgil P., Iyengar R., Luker K.E., Rehemtulla A., Luker G.D. NanoLuc reporter for dual luciferase imaging in living animals. Mol. Imaging 2013, 12:1-13.
30. Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., Pavletich N.P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274:948-953.
31. Freedman D.A., Epstein C.B., Roth J.C., Levine A.J. A genetic approach to mapping the p53 binding site in the MDM2 protein. Mol. Med. 1997, 3:248-259.
32. Nicholson J., Scherl A., Way L., Blackburn E.A., Walkinshaw M.D., Ball K.L., Hupp T.R. A systems wide mass spectrometric based linear motif screen to identify dominant in-vivo interacting proteins for the ubiquitin ligase MDM2. Cell. Signal. 2014, 26:1243-1257.
33. T. Machleidt, NanoBRET and NanoBiT: New Tools for the Analysis of Protein-Protein Interactions in Living Cells,. http://ita.promega.com/products/pm/uk/seminar-tour/2015/thomas-machleidt/.